U.S. Markets open in 8 hrs 15 mins
  • S&P Futures

    4,148.50
    +6.75 (+0.16%)
     
  • Dow Futures

    32,840.00
    +48.00 (+0.15%)
     
  • Nasdaq Futures

    13,205.25
    +22.00 (+0.17%)
     
  • Russell 2000 Futures

    1,944.80
    +3.70 (+0.19%)
     
  • Crude Oil

    90.59
    -0.17 (-0.19%)
     
  • Gold

    1,801.80
    -3.40 (-0.19%)
     
  • Silver

    20.68
    +0.07 (+0.32%)
     
  • EUR/USD

    1.0197
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    2.7650
    0.0000 (0.00%)
     
  • Vix

    21.29
    +0.14 (+0.66%)
     
  • GBP/USD

    1.2085
    +0.0003 (+0.03%)
     
  • USD/JPY

    134.9190
    -0.0540 (-0.04%)
     
  • BTC-USD

    23,871.27
    +524.22 (+2.25%)
     
  • CMC Crypto 200

    557.35
    +14.47 (+2.67%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • Nikkei 225

    27,985.49
    -263.75 (-0.93%)
     

Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early Parkinson's disease.

  • Prasinezumab is an anti-alpha synuclein antibody.

  • The event has triggered a $60 million milestone to Prothena from its worldwide collaboration with Roche Holding AG (OTCMKTS: RHHBY).

  • Prothena has previously received $75 million in payments from Roche as part of this collaboration.

  • PADOVA is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of prasinezumab in patients with early Parkinson's disease who are on stable symptomatic medication.

  • The study will enroll approximately 575 patients. The primary endpoint is time to meaningful progression on motor signs of the disease, as assessed by over 5 point increase from baseline in the Parkinson's Disease score.

  • Price Action: PRTA shares closed 5% lower at $23.39 on Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.